- Cart - 0 item(s)
- $0.00
Your shopping cart is empty!
- Chemistry
- Inhibitors
- Natural Products
- Alkaloids
- Amino acid
- Anthraquinones
- Cerebrosides
- Chalcones
- Coumarins
- Diterpenoids
- Flavonoids
- Iridoids
- Lignans
- Lipids
- Miscellaneous
- Monoterpenoids
- Other terpenes
- Phenols
- Phenylpropanoids
- Quinones
- Saccharides
- Sesquiterpenoids
- Steroids
- Tetraterpenoids
- Thiophenes
- Triterpenoids
- Xanthones
- Polyphenols
- Stibene glucosides
- Oligose
- Anthocyanins
- Miscellaneous
- Chromones
- Terpenoids
- Indoles
- Procyanidins
- Aliphatics
- Botanical Cyclopeptides
- ADCs
- Antibodies
- Multiplex IHC
- Material Science
- Others
[CAS NO. 1353625-73-6] Presatovir
| Ships within | Stock | Price | Qty | Total |
Please click "REQUEST A QUOTE" button if there is no stock, or you need other sizes or custom synthesis.
| Catalog: | HY-16727 |
| Brand: | MCE |
| CAS: | 1353625-73-6 |
Overview
| MDL | - |
|---|---|
| Molecular Weight | 532.06 |
| Molecular Formula | C24H30ClN7O3S |
| SMILES | O=C(C(C=C(Cl)C=C1)=C1NS(C)(=O)=O)N(CCCC2)[C@@H]2C3=NN4C(N=C(N5CC[C@H](N)C5)C(C)=C4)=C3 |
3 Publications Citing Use of MCE
Summary
IC50 & Target
EC50: 0.43 nM (RSV) [1]
In Vitro
Presatovir is a novel, orally bioavailable RSV fusion inhibitor discovered following a lead optimization campaign on a hit originated from a phenotypic RSV antiviral high-throughput screen. Presatovir exhibits potent activity against a wide range of RSV A and B clinical isolates with a mean EC 50 value of 0.43 nM [1] . GS-5806 inhibits pre to post triggered conformational changes of RSV F protein, suggesting a possible mechanism for antiviral activity [2] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
Presatovir demonstrates dose-dependent (0-30 mg/kg) antiviral efficacy in a cotton rat model of RSV infection. Oral bioavailability in preclinical species ranges from 46 to 100%, with penetration of the compound into the lung tissue demonstrated in Sprague-Dawley rats. Multidose oral treatment of Presatovir appears safe in adults, and in healthy human volunteers experimentally infected with RSV, a potent antiviral effect and reduction in disease severity is observed in the high dose group. A group treated with a lower dose of Presatovir allows for a PK-PD relationship to be established to help guide future dose selections [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT02254408 | Gilead Sciences |
Respiratory Syncytial Virus
|
January 23, 2015 | Phase 2 |
| NCT01801293 | Gilead Sciences |
RSV Infection
|
March 2013 | Phase 1 |
| NCT01797419 | Gilead Sciences |
Respiratory Syncytial Virus Infections
|
May 2013 | Phase 1 |
| NCT02254421 | Gilead Sciences |
Respiratory Syncytial Virus Infection
|
January 31, 2015 | Phase 2 |
| NCT02534350 | Gilead Sciences |
Respiratory Syncytial Virus (RSV)
|
December 31, 2015 | Phase 2 |
| NCT02135614 | Gilead Sciences |
Respiratory Syncytial Virus Infection
|
June 9, 2014 | Phase 2 |
| NCT01756482 | Gilead Sciences |
Respiratory Syncytial Virus Infections
|
November 2012 | Phase 2 |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : 6 mg/mL ( 11.28 mM ; Need ultrasonic and warming)
H 2 O : < 0.1 mg/mL (ultrasonic;warming;heat to 60°C) (insoluble)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 1.8795 mL | 9.3974 mL | 18.7949 mL |
| 5 mM | 0.3759 mL | 1.8795 mL | 3.7590 mL |
| 10 mM | 0.1879 mL | 0.9397 mL | 1.8795 mL |
-
1.
-
2.
Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: ≥ 0.6 mg/mL (1.13 mM); Clear solution
-
3.
Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 0.6 mg/mL (1.13 mM); Clear solution
-
4.
-
5.
Add each solvent one by one: 5% DMSO >> 95% (20% SBE-β-CD in saline)
Solubility: ≥ 0.48 mg/mL (0.90 mM); Clear solution
References
- [1] Mackman RL, et al. Discovery of an oral respiratory syncytial virus (RSV) fusion inhibitor (GS-5806) and clinical proof of concept in a human RSV challenge study. J Med Chem. 2015 Feb 26;58(4):1630-1643.
- [2] Samuel D, et al. GS-5806 inhibits pre- to postfusion conformational changes of the respiratory syncytial virus fusion protein. Antimicrob Agents Chemother. 2015 Nov;59(11):7109-12.
Arctom is a premier supply platform offering over 600K unique items of Building Blocks, Bioactive Molecules, Natural Products, ADC PEG Linkers, Antibodies, and other Research Chemicals for global pharmaceutical, biotech, university, and industrial customers. We accelerate your research by providing better and faster purchasing experience & services.